Skip to main content
Submitted by makehstory on

Identify the Window
of Opportunity and
Rewrite the Story
of Hidradenitis
Suppurativa ()

Let's Make HStory

Actual patient living with HS

 

HS in the US

HS prevalence in the US is an estimated 0.1-1%, or about 3,300,000 patients, with the highest disease rates reported in1:

  • Female patients
  • Patients in their 20s & 30s
  • African American patients

Early detection and
intervention is everything

As clinicians, when we achieve a deeper understanding of HS, we can intervene sooner by diagnosing and addressing early to slow disease progression.2-4 Addressing HS during the “window of opportunity,” when anti-inflammatory attempts will be most effective, may alter the natural HStory of the disease.4

Open the window of opportunity

Actual patient living with HS

Hear how Dr. So Yeon Paek is making HStory as she provides clarity on this often overlooked disease.

EXPLORE THE VIDEO CONTENT SUITE

HS Patient Facts

Patients with a family history of HS5

Nearly
1 in 3

Percentage of patients who visit a physician for HS symptoms before an appropriate HS diagnosis is made6

~64%

Percentage of patients who experience
daily flares6

23%

A delayed diagnosis markedly contributes to disease progression, additional comorbid conditions, and an increased number of surgically treated sites.2,3

Facing HS head on

HS is an immune-mediated, inflammatory condition that can be progressive and pervasive.7,8

It is characterized by recurring abscesses, inflammatory nodules, and tunnels and scars, commonly occurring in intertriginous skin.7 The chronic immune response eventually leads to severe pain, purulent discharge, tissue damage, and scarring.8,9

Disease severity is typically graded using the Hurley Clinical Staging System.10

DIVE INTO DIAGNOSIS

HS can feel unbeatable. But it’s manageable.

Understanding HS can lead to earlier diagnosis and help patients get ahead of the recurrent flares that can lead to social, emotional, and psychological devastation.8,11

Social withdrawal or isolation
Social withdrawal or isolation11
Diminished intimacy
Diminished intimacy8,11
Unemployment
Unemployment8,11
Substance use disorder
Substance use disorder12

Comprehensive care should include screening for and managing associated comorbidities that contribute to poor health and impaired life quality.12

SCREEN FOR COMORBIDITIES

 
 
Common comorbid conditions include:
  • DepressionDepression8,11
  • AnxietyAnxiety8,11
  • Metabolic syndromeMetabolic syndrome12
  • SpondyloarthritisSpondyloarthritis12

Taking charge of treatment

Current guidelines indicate multiple therapies–including biologics, antibiotics, steroids, and surgery–can help control the impact of the disease.13,14

Managing HS often requires systemic treatment that can effectively address the severity of disease on a case-by-case basis.14 Addressing HS during the “window of opportunity,” when anti-inflammatory attempts will be most effective, may alter the natural HStory of the disease.4

A better understanding of the underlying pathophysiology can help with developing a comprehensive standard of care.15

LEARN MORE ABOUT HS MANAGEMENT
Alt Tag Goes Here

Actual patient living with HS

References

  1. Garg A, Kirby JS, Lavian J, et al. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol. 2017;153(8):760-764.
  2. Kokolakis G, Wolk K, Schneider-Burrus S, et al. Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system. Dermatology. 2020;236(5):421-430.
  3. Sayed CJ, Hsiao JL, Okun MM. Hidradenitis Suppurativa Foundation Women’s Health Subcommittee. Clinical epidemiology and management of hidradenitis suppurativa. Obstet Gynecol. 2021;137(4):731-746.
  4. Martorell A, Jfri A, Ochando G, et al. Present and future trends of biologic therapies and small molecules in hidradenitis suppurativa. J IMIDs. 2022;2(1):8-19.
  5. Scala E, Cacciapuoti S, Garzorz-Stark N, et al. Hidradenitis suppurativa: where we are and where we are going. Cells. 2021;10(8):1-19.
  6. Garg A, Neuren E, Cha D, et al. Evaluating patients’ unmet needs in hidradenitis suppurativa: results from the Global Survey of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol. 2020;82(2):366-376.
  7. Okun MM, Flamm A, Werley EB, et al. Hidradenitis suppurativa: diagnosis and management in the emergency department. J Emerg Med. 2022;63(5):636-644.
  8. Sabat R, Jemec GB, Matusiak Ł, et al. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):1-20.
  9. Schneider-Burrus S, Tsaousi A, Barbus S, et al. Features associated with quality of life impairment in hidradenitis suppurativa patients. Front Med (Lausanne). 2021;8(676241):1-9.
  10. Lee EY, Alhusayen R, Lansang P, et al. What is hidradenitis suppurativa? Can Fam Physician. 2017;63(2):114-120.
  11. Matusiak Ł. Profound consequences of hidradenitis suppurativa: a review. Br J Dermatol. 2020;183(6):e171-e177.
  12. Garg A, Malviya N, Strunk A, et al. Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol. 2022;86(5):1092-1101.
  13. Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019;81(1):91-101.
  14. Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619-644.
  15. Smith S, Okoye G, Sokumbi O. Histopathology of hidradenitis suppurativa: a systematic review. Dermatopathology. 2022;9:251-257.